Raise closed, search for fresh raises on Seedstage

Santa Rosa, CA

Funding development of a medical device to address sepsis and life-threatening inflammatory conditions.

• Mission: Developing XGal-3®, a groundbreaking medical device aimed at addressing the root cause of sepsis by targeting and removing the Galectin-3 protein, which drives harmful inflammation in severe conditions.  
• Innovation: XGal-3® functions similarly to dialysis, filtering harmful proteins from the blood to halt the progression of sepsis, offering a potential life-saving treatment for ICU patients.  
• Scientific Validation: Supported by over 60 patents and NIH grants, with extensive research backing the technology’s potential to transform sepsis care and address a critical gap in current treatment options.  
• Health Impact: Aims to significantly reduce sepsis-related mortality rates in ICUs, with broader applications being explored for treating kidney disease, cancer, and other inflammatory conditions.  
• Growth Vision: With a focus on safety and efficacy trials with the FDA, Eliaz Therapeutics is positioning XGal-3® to become a standard treatment for sepsis and related conditions, with global impact potential.  
• Leadership & Expertise: Led by a team with deep expertise in medicine and biotechnology, the company is committed to advancing a device that targets the underlying causes of sepsis, rather than just managing its symptoms.

Eliaz Therapeutics is raising funds to advance XGal-3®, a groundbreaking medical device designed to address the root cause of sepsis by targeting Galectin-3, a protein that drives harmful inflammation during sepsis and other severe conditions. With over 60 patents and validation from NIH grants, XGal-3® works by filtering harmful proteins from the blood, halting the deadly progression of sepsis, and potentially reducing high mortality rates in ICUs.

This funding will support critical safety and efficacy trials with the FDA, ultimately aiming to bring XGal-3® to market as a standard treatment in ICUs. Eliaz Therapeutics envisions XGal-3® as a versatile platform with broader applications in treating kidney disease, cancer, and other inflammatory diseases, with an immediate focus on transforming sepsis care globally.

Company Info

Eliaz Therapeutics develops XGal-3®, a device targeting Galectin-3 to treat sepsis and related inflammatory diseases.

Eliaz Therapeutics is a biotechnology company focused on developing XGal-3®, an innovative medical device designed to treat sepsis by targeting and removing the Galectin-3 protein from the bloodstream, a key driver in the sepsis inflammatory process. The device functions similarly to dialysis, separating plasma and removing harmful proteins before returning cleansed blood to the patient, potentially halting the deadly progression of sepsis within hours.

With over 60 patents in 34 countries, XGal-3® is backed by extensive research, including two prestigious NIH grants, and aims to address a significant gap in sepsis treatment by targeting the underlying cause rather than just the symptoms. Led by a team with deep expertise in medicine, biotechnology, and research, Eliaz Therapeutics envisions XGal-3® as a vital tool in intensive care units worldwide, while exploring broader applications in diseases related to inflammation and fibrosis.